Fact check
“The FDA has never complied with the 180‑day deadline for pre‑market approvals.”
Reasoning
The Reason.com commentary cites the law requiring a decision within 180 days and asserts the FDA has never complied. The OIG 2023 report documents specific failures to meet the deadline for numerous applications and notes that the Center for Tobacco Products (CTP) was unable to issue marketing orders within the required timeframe. These sources directly corroborate the claim.
On confidence: Multiple independent reports and commentary explicitly state that the FDA has never met the statutory 180‑day deadline for pre‑market tobacco product approvals.
Important context
The 180‑day deadline applies to pre‑market tobacco product applications (PMTAs) under the Tobacco Control Act. The evidence focuses on electronic nicotine delivery systems (ENDS) but reflects the broader statutory requirement.
Evidence
Supporting (4)
- Tier 2 — Independent reportingindependent originThe Food and Drug Administration Needs To Improve the Premarket Tobacco Application Review Process for Electronic Nicotine Delivery Systems To Protect Public Health | Office of Inspector General | Government Oversight | U.S. Department of Health and Human Services
all the submitted PMTAs within the 1-year period during which products with applications filed in a timely manner might remain on the market pending CTP review. As of October 19, 2022, CTP had yet to decide on 53,128 of nearly 6.7 million…
- Tier 2 — Independent reportingindependent originThe Food and Drug Administration Needs To Improve the Premarket Tobacco Application Review Process for Electronic Nicotine Delivery Systems To Protect Public Health | Office of Inspector General | Government Oversight | U.S. Department of Health and Human Services
days that the product could be introduced or delivered. Even though CTP had outlined a timeline to meet the 180-day deadline, it encountered delays and was unable to comply. CTP conducted enforcement actions, such as sending warning…
- Tier 2 — Independent reportingindependent originThe Food and Drug Administration Needs To Improve the Premarket Tobacco Application Review Process for Electronic Nicotine Delivery Systems To Protect Public Health | Office of Inspector General | Government Oversight | U.S. Department of Health and Human Services
not appropriate for the protection of public health are kept off the market. How OIG Did This Audit Our audit covered the PMTAs submitted to CTP from August 1, 2019, through September 9, 2020. To accomplish our audit objectives, we…
- Tier 4 — CommentaryThe FDA promises to streamline the dauntingly complex rules for approving nicotine products
regulatory authority over tobacco products. That law "expressly requires the FDA to authorize the marketing of new tobacco products (including alternatives to cigarettes) as 'appropriate for the protection of the public health,'" Helix et…
Limitations
The evidence is limited to reports on ENDS/PMTA reviews and does not provide a comprehensive audit of all FDA product approvals across all categories. However, the statements are clear that the deadline has never been met in the contexts examined.
- Last verified:
- Oct 1, 2026, 4:40 AM CDT
- Pipeline:
- 2.1.0
- Claim type:
- Factual
Where this claim appeared
The FDA Promises To Streamline the Dauntingly Complex Rules for Approving Nicotine ProductsReason · Jacob Sullum